drugset / Trial / NCT04408898
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A\*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer.
Timeline
- Start
- 2020-07-02
- Primary completion
- 2021-12
- Completion
- 2021-12
Outcome
Outcome not reported
Stopped (Enrollment): “Challenges with recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADP-A2M4 | Cell therapy | 1e+09 cells | Intravenous |
| Subject | ADP-A2M4 | Cell therapy | 1e+10 cells | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | — |